PMN
ProMIS Neurosciences, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$12.55
−2.71%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- -54.7%
- EPS
- —
- Free cash flow
- -77.3%
- Operating cash flow
- -77.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +73.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- -3.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026